The data appeared in Science Translational Medicine and resulted from a collaboration with the National Institute of Allergy and Infectious Diseases in the US.
Researchers used MaxCyte’s Flow Electroporation Technology and were able to correct mutation in the CYBB gene.
"We are very encouraged by the preclinical data obtained in this study, which showed the effectiveness of [our] proprietary, high-performance technology to correct for genetic mutations, especially in cases where traditional viral vector-based gene insertion methods have not been effective," said the company’s chief scientific officer, Madhusudan Peshwa.
"This study also demonstrates the commitment of MaxCyte to fostering development of novel cell therapies and supporting our partners' use of our delivery platform. MaxCyte invests early in translational development of non-virally engineered and ex vivo gene-edited cell therapy products.”